21 results
Thumbnail

D1.349 - Early Diagnosis of WHIM Syndrome in Infancy: A Case with a De Novo CXCR4 Mutation

Thumbnail

D1.348 - Retrospective Evaluation of Laboratory and Clinical Characteristics of Pediatric Patients Diagnosed with IgG Subclass Deficiency and Receiving Intravenous Immunoglobulin Replacement Therapy

Thumbnail

D1.350 - Selective IgA deficiency and its association with allergic and autoimmune diseases

Thumbnail

D1.351 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular associations

Thumbnail

D1.353 - A Rare Cause of Recurrent Infections: SIFD Syndrome

Thumbnail

D1.354 - Possible Association of a MYOF Loss-of-Function Variant With Recurrent Angioedema: Overlap Between Chronic Spontaneous Urticaria and Normal-C1 Hereditary Angioedema? A Case Report

Thumbnail

D1.355 - Familial Recurrent Angioedema with Normal C1-Inhibitor: A Clinical Case Series Suggestive of HAE with Normal C1-INH

Thumbnail

D1.356 - Atypical association of anti-EJ and anti-RNA polymerase III antibodies in a patient referred for interstitial lung disease

Thumbnail

D1.357 - Atypical case of common variable immune deficiency with granulomatous lymphocytic interstitial lung disease

Thumbnail

D1.363 - Long-Acting Prophylactic Injection BW-20805: Remarkable and Sustained HAE Attack Reduction — Updated Analysis from an Ongoing Phase 2 Study

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases